Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
Not yet recruiting
Bristol-Myers Squibb
Phase 2
2022-09-01
The current study assesses the tolerability and efficacy of combination therapy with PD-1
(nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young
adults with craniopharyngioma.
Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
Not yet recruiting
Day One Biopharmaceuticals, Inc.
Phase 2
2022-09-01
The current study assesses the tolerability and efficacy of combination therapy with PD-1
(nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young
adults with craniopharyngioma.
Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
Not yet recruiting
Sabine Mueller, MD, PhD
Phase 2
2022-09-01
The current study assesses the tolerability and efficacy of combination therapy with PD-1
(nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young
adults with craniopharyngioma.
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy
Not yet recruiting
SIOPe Brain Tumor Group LOGGIC Consortium
Phase 3
2022-10-01
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the
efficacy, safety, and tolerability of DAY101 monotherapy versus standard of care (SoC)
chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating
rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
